IRulya Therapeutics Inc. Common Stock
IRLA
85 hedge funds and large institutions have $99.5M invested in IRulya Therapeutics Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 32 reducing their positions, and 22 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8.25% less ownership
Funds ownership: 64.39% → 56.13% (-8.3%)
11% less call options, than puts
Call options by funds: $4.92M | Put options by funds: $5.54M
13% less funds holding
Funds holding: 98 → 85 (-13)
34% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 32
59% less capital invested
Capital invested by funds: $243M → $99.5M (-$143M)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.95M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.09M |
| 3 |
PP
PDT Partners
New York
|
+$1.91M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.02M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$710K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$18.4M |
| 2 |
Millennium Management
New York
|
-$3.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.41M |
| 4 |
Walleye Capital
New York
|
-$1.73M |
| 5 |
Morgan Stanley
New York
|
-$1.48M |
IRLA Hedge Fund Activity: Q1 2022 in Review
85 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q1 2022, worth a combined $99.5M — down 59% from $243M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of IRLA and 9 opened new positions — a net loss of 13 holders — while 32 trimmed existing stakes and 21 added.
The largest buyer was JP Morgan Chase, adding an estimated $3.95M. The largest seller was Capital International Investors, exiting entirely with an estimated $18.4M sold.
- 85 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q1 2022, down from 98 in Q4 2021.
- Funds reported $99.5M of IRulya Therapeutics Inc. Common Stock stock for Q1 2022, down 59% quarter-over-quarter.
- 9 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q1 2022 and 22 closed out, a net change of -13 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q1 2022 was JP Morgan Chase, an estimated $3.95M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q1 2022 was Capital International Investors, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2022.